Gong et al. used a combination of FXR agonist and anti-PD-1 antibody to highlight insights into the use of the tumor immune microenvironment against HCC for the treatment of other tumors (Gong et al., 2021). Here, PDCD1 is linked to hepatocellular carcinoma.